Targeting p95HER2 to help HER2-positive breast cancer that stops responding to current therapies
Project 4
This project is developing new ways to target p95HER2, a shortened form of HER2, to help people whose HER2-positive breast cancer no longer responds to available antibody treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11176770 on NIH RePORTER |
What this research studies
You would hear about work focused on p95HER2, a truncated form of HER2 found in some breast tumors that can cause resistance to standard HER2 antibodies. Researchers are designing treatments that bind or otherwise target p95HER2 and testing them in laboratory models and on tumor samples from patients. The team is studying how p95HER2 drives treatment resistance so they can design drugs that overcome that resistance. If lab results are promising, the work would support early clinical testing at Mayo Clinic or partner sites.
Who could benefit from this research
Good fit: Ideal candidates would be people with HER2-positive breast cancer, especially those whose tumors express p95HER2 or who have stopped responding to trastuzumab, pertuzumab, or similar HER2-directed therapies.
Not a fit: People with HER2-negative breast cancer or tumors that do not express p95HER2 are unlikely to benefit from these specific approaches.
Why it matters
Potential benefit: If successful, this could lead to new therapies that work for patients whose HER2-positive tumors resist current antibody treatments.
How similar studies have performed: Existing HER2-targeted antibodies and antibody–drug conjugates have greatly helped many patients, but directly targeting p95HER2 is a newer approach with limited clinical data so far.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Lucas, Peter C — Mayo Clinic Rochester
- Study coordinator: Lucas, Peter C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.